Abstract
Early bone marrow transplant is now standard treatment for infants with severe immunodeficiencies such as Wiskott-Aldrich Syndrome (WAS), but results in older children and adults are poor. Non-myeloablative transplant has shown promise in the treatment of older children, who are likely to have active infections and organ damage. We describe a non-myeloablative transplant of a 26-year-old man with WAS, undertaken because of severe infections and vasculitis. Partial engraftment and immunorestoration were achieved. The patient is well 1 year post transplantation.
MeSH terms
-
Adult
-
Alemtuzumab
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / therapeutic use
-
Bone Marrow Transplantation / methods*
-
Cyclophosphamide / therapeutic use
-
Humans
-
Immunoglobulins, Intravenous
-
Immunosuppressive Agents / therapeutic use
-
Male
-
Penicillin V / administration & dosage
-
Transplantation Chimera
-
Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage
-
Vidarabine / analogs & derivatives
-
Vidarabine / therapeutic use
-
Wiskott-Aldrich Syndrome / therapy*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Immunoglobulins, Intravenous
-
Immunosuppressive Agents
-
Alemtuzumab
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Cyclophosphamide
-
Vidarabine
-
fludarabine
-
Penicillin V